Genmab

	26/3 18:40 af Bella1	Jan van de Winkel valgt som bestyrelsesmedlem i Novo!
	23/3 10:49 af StockBull	RSI dagkort tæt på de 27 - købt flere i 1592 - GAK under 1800
	23/3 10:00 af concillado	Så er vi nede i 1500-regi
	23/3 08:12 af ProInvestorNEWS	Genmabs anbefaling sættes op til "køb" hos Baptista (link)
	21/3 10:20 af E L	also - Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: first disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study
	21/3 10:20 af E L	looks like we may get some data on Rina-s early april -Rinatabart sesutecan (Rina-S) plus bevacizumab (BEV) for patients (pts) with recurrent ovarian cancer (OC): First disclosure from cohort D2 of the phase 1/2 RAINFOL-01 study Monday, April 13, 2026 via (link)
	20/3 21:26 af Raun	Håber godt nok han får ret denne gang :-)
	20/3 21:16 af Solsen	RSI i 27 på adr aktien. Købssignal jf SB :-)
	20/3 21:10 af Raun	Huhej hvor det går - 1600 står for fald...
	20/3 18:16 af E L	more than twice the day volume in the close. major risk off before the weekend or does it have something to do with today's option expiration
	20/3 17:17 af E L	we were all waiting for your contribution ;-)
	20/3 16:39 af npo	som i de svenske skove - det der larmer mest er stilheden - var AGM igår en non-event, eller er deltagerne i koma ?
	19/3 18:11 af concillado	Aaahh.. thx for clarifiation, EL!
	19/3 17:34 af E L	is the same. ' the Company’s holding of treasury shares will be reduced by 1,900,000 shares of a nominal value of DKK 1 each. '
	19/3 17:25 af concillado	Der står 1,9 mio DKK... ikke stk. ;-)
	19/3 16:57 af bikube	Bestyrelsens eget forslag til deres "løn" for året -26 blev åbenbart taget af bordet. Nyt forslag kommer senere, og skal vedtages af aktionærerne. Kan det gøres uden en ny generalforsamling ?
	19/3 16:17 af bikube	Sletning af 1,9 Mio aktier er jo ikke så ringe.
	19/3 14:35 af E L	The Annual General Meeting 2026 will take place on Thursday, March 19, at 2:00 PM CET (link)
	19/3 09:53 af E L	abstract at the AACR Annual Meeting , but doubt that will be pursued
	19/3 09:52 af E L	1761 / 6 - Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models (link)
	18/3 10:58 af concillado	Hvis ikke I allerede har gjort det, så indgiv jeres stemmer til generalforsamlingen online på forhånd via Genmabs investorportal, hvis ikke I møder op eller har en repræsentant for at kunne stemme på selve generalforsamlingen i morgen kl. 14. Alle stemmer tæller, hvis I er enige/uenige med beslutningerne.
	17/3 12:52 af concillado	Robotterne (folkene bag) venter lige på generalforsamlingen, og så vil det vise sig om det bliver en sommer med aktietørke for Genmab eller et sommerrally.
	16/3 16:12 af lahn1	Så er buy-back programmet slut og det er tid til at vi skal op igen. ;-)
	14/3 03:58 af StockBull	For at nå mit RSI-target på 27–30 på dagskortet kræver det sandsynligvis et yderligere fald på 5–10 % (til ca. 1.550–1.620 DKK) over de kommende uger, med vedvarende nedadgående momentum. Det er ikke hugget i sten, at vi skal under RSI 30, men historisk set sker ekstremt oversolgte dips (RSI ≤ 30) ca. hver 6–8 måneder i gennemsnit (ca. 206 dage mellem events de sidste 13 år). Sidste gang var i april 2025.

	13/3 19:11 af Raun	Argh.... Måske ikke lige det dobbelte, men enig i at kursen burde ligge et helt andet leje..... Det skræmmende er at hovedparten af analysehusene har haft target kurser et godt stykke over 2000 igennem et par år, og de bliver ufortrødent ved. - Hvilket faktisk er ret usædvanligt for en faldende aktie - der plejer de faktisk at følge med ned...... Hvorom alting er, så siger markedet noget andet..
	13/3 18:33 af gdn55	Det er den jo ikke værd idag. Sådan er det jo med aktier, men hvis man bare gider at sætte sig lidt ind i tingene er den sansyndelig vis mindst det dobbelte værd.
	13/3 18:19 af Raun	Hvis Gordon er på gin, så sidder han nok og skåler med kollegerne...
	13/3 18:11 af Bella1	Ham Gordon, må være på gin! - God weekend:-)
	13/3 17:15 af E L	James Gordon CFA Barclays Buy Kr.2,500.00 Maintained Today 13-3-26
	12/3 19:58 af Raun	1722 i US lige nu - er det bare business as usual?
	10/3 20:18 af peter12	Fra Leerink webcast I dag med CCO og CFO: De regner ikke med større M&A 2 ph3 readouts for Epco i 2026 (1L I løbet af året og 2L i H1) 2 readouts for RhinaS og Peto (sidst på året) De forventer at Pato kan sælge 1mia$ i 2029
	10/3 17:59 af concillado	As long as Genmab can have a strategic partnership with this new "sister-company" as well, is what I am more interested in. As these two individuals clearly have the abillity and focus to innovate new "knock-your-socks-off" products! ;-)
	10/3 13:01 af E L	(link)
	10/3 13:00 af E L	jeez, BioNTech co-founders Ugur Sahin and Özlem Türeci will leave and establish an independent biotechnology company to research and develop next-generation mRNA innovations; management transition by end of 2026
	10/3 11:45 af E L	TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy (link)
	10/3 11:42 af E L	3 Acasunlimab posters at the European Lung Cancer Congress in Copenhagen later in March. Oh well, it is what it is. (link)
	9/3 16:14 af E L	Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial / Amlenetug (link)
	9/3 15:35 af gentogen	Early completion of randomization underscores the significant unmet need in MSA,
	9/3 15:34 af gentogen	H. Lundbeck A/S (Lundbeck) today announced that the last patient has been randomized in MASCOT (NCT06706622), a global Phase 3 clinical trial evaluating amlenetug in people with multiple system atrophy (MSA)
	8/3 21:25 af gentogen	Sandt nok, men dog fra en spritny artikel om det
	8/3 13:12 af peter12	Det er vist en gl. nyhed fra december (link)
	8/3 01:43 af gentogen	These findings suggest the potential of epcoritamab combined with standard chemoimmunotherapy as an effective salvage treatment for patients with R/R DLBCL.
	8/3 01:42 af gentogen	Thanks (again) EL. From 09.30 link: As of January 15, 2025 (median follow-up 40.4 months), overall response rate (primary endpoint) was 79%, and complete response rate was 69%. !!!
	7/3 10:47 af E L	Healio Disruptive Innovators Awards 2026, nominees for the Industry Breakthrough awards (goes to a product that stands out as a major disruption to the practice of hematology/oncology.) , 2 of the 6 are Genmabs , Dara and Epco (link)
	7/3 10:45 af KWC	Tak EL -... :-)
	7/3 10:40 af E L	On Tec-Dara, many raving reviews on socials and media like "MajesTEC-3 showed unprecedented efficacy, supporting a new standard of care in relapsed/refractory multiple myeloma patients ... The results represented "the greatest PFS treatment effect we've seen to date," María-Victoria Mateos MD said" (link) , but Genmab still lost almost 50dkk..., difficult market...
	7/3 10:30 af E L	#Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell #lymphoma (link) (link)
	6/3 18:19 af bikube	Earlyer to day it was only European oil, which were green, Exxon & Chevron were red.
	6/3 16:38 af E L	it is what it is gdn55 , not a lot we can do about it... some investors will simply have to sell because of their losses in those 2, others get dragged down with related indices that suffer and some will loose confidence in the biopharma sector althogether... and the middle east certainly doesn't help, i see only red on my screens, except for VIX, gas and oil...
	6/3 16:18 af Raun	Der har jo ikke været logik i aktien i årevis. - Hvorfor skulle det starte nu?..... TAerne har igennem de serene år ramt helt forkert med Genamabs mellemlange til langsigtede kursudvikling. - Håber dog at @Stockbull rammer med hans seneste forecast - det ligner i hvert fald et sandsynligt scenarie...